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Abstract
Background: The direct isolation of integron gene cassettes from cultivated and environmental microbial sources allows an
assessment of the impact of the integron/gene cassette system on the emergence of new phenotypes, such as drug
resistance or virulence. A structural approach is being exploited to investigate the modularity and function of novel
integron gene cassettes.
Methodology/Principal Findings: We report the 1.8 A˚ crystal structure of Cass2, an integron-associated protein derived
from an environmental V. cholerae. The structure defines a monomeric beta-barrel protein with a fold related to the effector-
binding portion of AraC/XylS transcription activators. The closest homologs of Cass2 are multi-drug binding proteins, such
as BmrR. Consistent with this, a binding pocket made up of hydrophobic residues and a single glutamate side chain is
evident in Cass2, occupied in the crystal form by polyethylene glycol. Fluorescence assays demonstrate that Cass2 is
capable of binding cationic drug compounds with submicromolar affinity. The Cass2 module possesses a protein
interaction surface proximal to its drug-binding cavity with features homologous to those seen in multi-domain
transcriptional regulators.
Conclusions/Significance: Genetic analysis identifies Cass2 to be representative of a larger family of independent effector-
binding proteins associated with lateral gene transfer within Vibrio and closely-related species. We propose that the Cass2
family not only has capacity to form functional transcription regulator complexes, but represents possible evolutionary
precursors to multi-domain regulators associated with cationic drug compounds.
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Introduction
The Vibrio genus is ubiquitous and abundant throughout the
aquatic environment. It is clear that lateral gene transfer (LGT)
events play a major role in the evolution and adaptation of this
organism, with genetic interchange of Vibrio genes observed over a
wide range of phylogenetic distances [1]. Our analysis of V. cholerae
and V. vulnificus genomes suggests up to 20% of their content to
have arisen via this route. The continued emergence of novel
pathogenic clones carrying diverse combinations of phenotypic
and genotypic properties significantly hampers control of the
disease [2]. The emergence of V. cholerae O139, one of the two
strains responsible for epidemic Asiatic cholera, appears to be a
result of LGT from multiple and diverse descendants of the
seventh pandemic O1 El Tor strain [2,3]. Recent studies have
indicated that the O1 and O139 associated virulence genes (or
their homologues) are also dispersed among environmental strains
of V. cholerae [4,5]. LGT and acquisition of virulence genes is then
a very likely mechanism for the emergence of pandemic strains of
V. cholerae from non-pathogenic environmental strains [6,7,8,9].
The mobilization and integration of mobile gene clusters carrying
genes for multiple antibiotic resistance, although not directly
implicated in the mechanism of pathogenicity, are also thought to
significantly influence the epidemiology of cholera [10].
One important mediator of LGT involves mobile gene cassettes
clustered in association with integrons [11]. Gene cassettes are
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captured by integrons via their intrinsic site-specific recombination
system [12,13,14] and constitute the smallest known mobilisable
genetic element [7,13,15]. Integrons themselves can be found on
mobile elements as well as in the chromosome [7,15]. While most
integron cassette arrays contain relatively small numbers of
cassettes, extremely large arrays (numbering 100–200) appear
particularly prevalent for Vibrio species [8,16]. Rearrangements
and deletions/insertions of large portions of these mobile gene
arrays appear to be common events [6,14], and arrays can display
high levels of diversity even in strains that are otherwise closely
related. Independent studies continue to show that gene cassettes
possess a very high proportion of genetic novelty, whether derived
from defined strains [8,16] or from metagenomic surveys [17,18].
In this work, we focus on one integron gene cassette (Vch_cass2)
isolated from a strain of V. cholerae resident within a brackish
coastal environment in north-eastern USA. Initial sequencing
identified the gene cassette to encode a domain with some
homology to the AraC superfamily of transcription activators,
generally implicated in the regulation of stress response and
virulence [19]. These regulators are well characterized to be
modular systems, and include the AraC, MarR and MerR protein
families [20]. Generally, these are organized with a DNA-binding
domain that acts as a positive regulator of transcription fused to an
effector domain which provides a binding site for a specific
chemical activator molecule [20,21]. The modularity of these
systems provides capacity for complex regulatory networks, which
can also incorporate the membrane transporters for extrusion of
multiple toxic agents or drugs [22]. In this way, for example, the
AraC and MerR multi-domain regulators are organised to be
capable of recognizing the same array of toxic compounds
extruded by the transporters they themselves transcribe [23].
Our recovery of a gene cassette encoding a single and
independent effector-like domain is noteworthy as a likely
evolutionary precursor to a transcription regulatory system within
Vibrio spp. The structural and functional characterisation of this
novel integron-associated protein, named here Cass2, was thus of
immediate interest as a potential drug-binding factor, particularly
as the integron/gene cassette system is strongly associated with the
emergence of antibiotic and drug resistance [11]. We found the
protein structure to be representative of several single-domain
homologues, often mobile, within the genomes of related aquatic-
dwelling bacterial species. The origin of the gene cassette within an
environmental Vibrio species points to its potential as a mobile
element facilitating the spread of drug resistance and the
emergence of novel phenotypes.
Results
An Independent Effector-Binding Domain Related to the
AraC_E_bind Superfamily
The gene cassette named Vch_cass2 was one of a group of
integron gene cassettes isolated from OP4G, an environmental
strain of V. cholerae derived from a brackish coastal pond in
Massachusetts (USA). Partial genomic sequencing has established
this strain to have strong sequence identity (.90%) with known
pathogenic strains of V. cholerae (Boucher, unpublished). The
encoded protein sequence, Cass2, displays signature motifs that
associate it with the superfamily AraC_E_bind (cl01368, sm00871
[24], pfam06445), named for the effector domain of the AraC/
XylS transcription activators [21]. Members of this superfamily
regulate diverse bacterial functions, including sugar catabolism
and responses to stress and virulence [19]. As outlined in Figure 1,
several multi-domain protein families incorporate an effector
domain of this type (usually C-terminal in position), often in
conjunction with a helix-turn-helix DNA-binding domain. This
allows transcription activation of cognate promoters to be enabled
through the highly conserved DNA-binding domain in response to
effector binding [21,25]. However, in the case of Vch_cass2,
sequence searches (both gene and protein levels) established it to
be representative of an entirely distinct family of independent
single-domain proteins, represented by over 1200 homologs across
a range of organisms. A phylogenetic analysis of these sequence
relatives (Figure 2) places Cass2 in a distinct clade (75–79%
amino acid identity) sourced from a variety of marine-dwelling
bacteria. While Cass2 clearly clusters with homologs from specific
Vibrio spp (bootstrap value of 100%), a related but distinct clade
displaying ,40% amino acid identity is evident within Shewanella
genomes. Representative protein sequences for members of these
two clades are aligned with that of Cass2 in Figure 3.
Importantly, like Vch_cass2, the genetic context for many of its
homologs indicate an association with LGT. Those relatives
displaying highest sequence homology are also encoded within
gene cassette elements (e.g. V. cholerae MZO-2 and AM-19226),
while others are found adjacent to transposon features (V. vulnificus
CMCP6).
Crystal Structure of Cass2
Structure determination by x-ray crystallography revealed the
protein Cass2 to be a monomer organised into a barrel-like form
comprising an antiparallel b-sheet of eight strands (Figure 4a).
Flanking the concave face of the central sheet are two separated
helical elements, in which helices a1 (residues 20–24) and a2 (31–
45) are aligned to one side, and helix a3 (104–118) to the other.
The topology of the domain highlights its pseudo two-fold
symmetry, which is based on repeating b-b-a-b-b motifs.
Subdomain I (residues 9–91) superimposes over subdomain II
(residues 1–8, 92–149) with an rmsd of 1.7 A˚ (calculated on 37 Ca
atoms), and directly aligns elements b2, a2, b3 and b4 with b6, a3,
b7 and b8, respectively. Despite the low sequence identity of the
two subdomains (,12%), the structural superposition coherently
maps side chains Phe14, Leu34, Trp35, Tyr56 and Val69 from
subdomain I to those of Phe97, Leu110, Trp111, Tyr136 and
Val142 in subdomain II. These recurring side chains stabilise
packing of the helices to the b-sheet and form critical elements of
the ligand-binding site.
Within both subdomains of Cass2, a relatively flexible loop is
located C-terminal to the helical portion, i.e. forming connections
Figure 1. Domain analysis of Cass2 sequence. Six groupings are
identified to contain AraC_E_bind (pfam06445) domains in a variety of
architectures. The number of sequences found in each grouping (May,
2010) is indicated by frequency.
doi:10.1371/journal.pone.0016934.g001
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between a2–b3 (residues 46–50) and a3–b7 (residues 119–130)
segments. These loops project from the top and bottom of the
sheet, respectively (orientation as depicted in Figure 4). Additional
areas of flexibility (as evidenced by elevated B-factors) reside within
subdomain I, provided by the loops connecting sheet strands b3–
b4 and b4–b5 of the structure.
The central cavity enclosed between the helices of Cass2 is
largely hydrophobic in nature, and aromatic side chains
predominate. However, a single acidic group (Glu134, originating
from strand b7) is buried deep within this cleft, flanking the pseudo
two-fold axis of the protein structure. The polarity of this side
chain is stabilised by hydrogen bonds to side chains of Tyr56,
Tyr136, and Trp111 (Figure 4B). Between the helical edges of the
cavity and directly above the topological switch-point of the sheet
(i.e. b3/b7), density is observed corresponding to a polyethylene
glycol (PEG) molecule captured during crystallization of Cass2.
Hydrophobic side chains from helices a2 (Trp35, Tyr39) and a3
(Pro104, Val107, Ile108, Trp111) and the b7/b8 interstrand loop
(Tyr136) are within 4 A˚ of this ligand. Some additional density can
be distinguished in our maps belonging to a second (non-definable)
ligand, extending further along this same cavity to Trp115.
The sequence alignment for the two distinct clades of Cass2
relatives from Vibrio and Shewanella (Figure 3) highlights that
conserved sequence segments are distributed throughout the
domain, most strongly within structural components making up
the central cavity. All of the side chains listed above as interacting
with bound PEG, as well as Glu134, are conserved across the
Cass2 sequence family (Tyr39 being conservatively replaced in
Shewanella strains) (Figure 3). The domain we define here thus
provides a common framework for a hydrophobic ligand chemistry.
Figure 2. Phylogenetic tree of Cass2 sequence with evolutionary distances. Bootstrap values $80% are shown over the internodes for 36
sequence homologues. Protein names are annotated as in the NCBI database and distinguished as: EB, transcription activator, effector binding; AraC,
transcription regulator, AraC family; HP, hypothetical protein or OP, orphan protein. Boxed clade contains sequence of interest; its relatives shown in
bold are known to be gene cassettes from integron cassette arrays.
doi:10.1371/journal.pone.0016934.g002
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Structural Relationship to Effector-Binding Domains
Searches for structural homologues of Cass2 revealed several
fold relatives with overlapping biological functions associated with
transcription regulation. Close spatial alignment was found to
putative transcription regulation protein from Staphylococcus aureus
(PDB 3LUR), the C-terminal domain of Rob transcription factor
from E. coli (PDB 1D5Y) [26], the C-terminal drug-binding
domain of the multi-drug efflux transporter regulator BmrR from
Bacillus subtilis (PDB 3D6Z) [27], and the gyrase inhibitory protein
GyrI/Sbmc from E. coli (PDB 1JYH) [28]. Despite their highly
diverse sequences (with only 15–26% identity to Cass2), these
three structures overlay well with that of Cass2, with rmsd values
of 1.9, 2.1, 2.5 and 2.4 A˚, respectively. Some members of the
BmrR subfamily, those of the MerR transcription activator
systems [20], had already been detected as remote relatives of
Cass2 within our initial sequence searches (outlined in Figure 1).
The E. coli Rob and GyrI domains are also members of the AraC/
XylS family of transcription factors; Rob is known to control
diverse regulons in prokaryotes [26] and GyrI plays a role in
protecting cells against the ribosomally synthesized peptide
antibiotic, microcin B17 [28]. Both GyrI and the C-terminal
domain of Rob have been speculated to be ligand-binding
domains, although the physiological ligands have not been
identified.
Amongst these five structural relatives (overlaid in Figure 5), all
display a similar disposition of secondary structure elements, the
greatest variation occurring in the region corresponding to helices
a2 and a1 of Cass2. A glutamate residue is preserved midway
across the sheet in all the proteins, stabilised within a hydrophobic
environment by surrounding Tyr side chains. The closest
structural homolog from Staphylococcus aureus (PDB 3LUR), retains
many of the hydrophobic side chains of the central cavity, but also
possesses a cluster of polar residues (Cys, Gln and Met) not present
in Cass2 (Figure 5C).
Figure 3. Multiple alignment of Cass2 and sequence homologs. Cass2 sequence is aligned with representative strains from Vibrio: Vv, Vibrio
vulnificus CMCP6 (AE016795.2); Vh, Vibrio harveyii ATCC-BAA-1116 (YP_001448888.1); VcM, Vibrio cholerae MZO-2 (ZP_01980402.1); VcA, Vibrio
cholerae AM-19226 (YP_002176820.1). Representative sequences are also included from the related clade of Shewanella homologs: Sb185, Shewanella
baltica OS185 (YP_0013657); Sb223, Shewanella baltica OS223, (YP_0023586). Secondary structure representation is as derived from crystal structure
of Cass2 (this work). Residues completely conserved in all homologs are shaded red, partially conserved residues are green. Active site residues are
starred, residues conserved in both subdomains I and II are also indicated (filled square).
doi:10.1371/journal.pone.0016934.g003
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For BmrR, known to bind a diverse group of hydrophobic
cationic compounds, several crystal structures of its complexes
have been determined: those with rhodamine 6G [27], tetra-
phenylphosphonium (TPP) [29] and berberine [27]. In our
structure of Cass2, the site occupied by PEG correlates closely
with the location of the cationic drug-binding cavity of BmrR
[27,29]. Within the BmrR-TPP complex [29], the phenyl ligand
substituents are seen to stack with hydrophobic side chains which
include Tyr51 (from strand b3) and Ile71 (strand b4). Nearby, the
charged Glu134 residue is stabilized by hydrogen-bonding to the
internal tyrosine side chains (Y33, Y68, Y110). Although not all
cavity-forming residues of Cass2 have directly conserved
sequence locations in BmrR, a similar binding framework is
common to both homologs, as depicted in Figure 5B.
The crystal structure of the Cass2-PEG complex displays a
markedly distinct conformation in the region C-terminal to helix
a2. Brennan’s team have proposed that hinge opening of BmrR in
the vicinity of helix a2, as well as repositioning of Tyr33
(corresponding to Cass2 Tyr39), results in the exposure of the
central cavity for interaction with the cationic ligand [29]. The
loop segment following helix a2 in Cass2 appears to be relatively
flexible in our structure, and it is thus feasible that access to the
ligand site in the gene cassette domain might occur by a similar
helix-opening mechanism, perhaps coupled in this case with
expulsion of the interior side chain Tyr39.
Ligand Binding Capacity of Cass2
Although the natural ligand of Cass2 is unknown, it is clear
that the domain contains a binding site suitable for hydrophobic/
cationic compounds, compatible with that seen in its structural
homologs. Tryptophan fluorescence was used to test for
interactions of Cass2 with a set of cationic compounds known
to associate with the related bacterial transcription regulators:
TPP, benzalkonium chloride, chlorhexidine [30]. The site-specific
mutant (E134Q)Cass2, designed to neutralise the electrostatic
effects of Glu134, was additionally probed in these titrations.
Cass2 contains three tryptophan residues, two of which (Trp35,
Trp111) are observed to be in close contact to PEG from helices
a2 and a3 within the binding cleft. The third side chain (Trp115
on helix a3) is somewhat more remote along the ligand cavity; it
exhibits multiple rotamer forms in the crystal, possibly due to
accommodation of other ligand molecules.
Initial fluorescence measurements in the presence of excess
quantities of all three compounds detected a blue shift (5 nm) from
the emission maximum of Cass2 in its apo form (349 nm). This is
consistent with loss of solvent exposure of the Trp residues, such as
might occur as the cavity closes upon ligand binding. For all three
compounds at sub-micromolar concentrations, significant quench-
ing (up to 60%) of the intrinsic fluorescence emission of Cass2
was observed in a concentration-dependent manner, as illustrated
for the titration with TPP in Figure 6. All interpolated KD values
were determined to be in the sub-micromolar range (Table 1). The
monovalent compound benzalkonium chloride, smallest of the
three compounds tested, displayed the strongest binding
(KD = 0.1 mM). The binding affinity determined for TPP
(KD = 0.2 mM) indicates a tighter interaction with Cass2 than
has been reported for the fold relative BmrR [27].
Mutation of the central glutamate sidechain of Cass2 had little
effect on its strength of binding to the monovalent compounds
tested (TPP, benzalkonium chloride). For the divalent compound
chlorhexidine, the affinity for the E134Q mutant appears to have
been somewhat enhanced (KD = 0.10 mM). The electrostatic role
of this glutamate thus appears to be tempered in the case of
Cass2, presumably due to the large number of hydrophobic
contacts within the internal binding cavity.
Our results are consistent with the earlier binding studies of
BmrR to three cationic compounds (Table 1) and crystal structures
obtained for the resulting complexes [27]. Substitution of the
Figure 4. Three-dimensional crystal structure of Cass2 at 1.8 A˚. A) Structure coloured by secondary structure elements: strands b1 (residues
1–6), b2 (9–18), b3 (52–57), b4 (67–73), b5 (85–89), b6 (92–100), b7 (131–135) and b8 (141–147) and helices a1 (20–24), a2 (31–45) and a3 (105–118). A
loop region of poor density connecting a3 to b7 (residues 120–122) is represented by dotted line. A bound molecule of PEG (yellow) occupies the
active site. N-terminal tag residues forming part of strand b1 are shaded orange. B) Depiction of side chains within 4 A˚ of the PEG molecule are
depicted, including surrounding water molecules. Polarity of Glu134 is neutralised by polar groups of Tyr 56, Tyr136 and Trp111 side chains.
doi:10.1371/journal.pone.0016934.g004
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central glutamate reside of BmrR (alanine and glutamine
variants) resulted in unpredicatable binding affinities for TPP,
berberine and rhodamine 6G. This led the Brennan group to
propose that the overriding enthalpic contributors to binding
affinity are the Van der Waals and stacking interactions between
protein and drug compound, rather than charge-charge interac-
tions [27]. This is consistent with our observation of little
alteration of tight binding of TPP to Cass2 with loss of the
glutamate charge.
Given we can demonstrate that Cass2 successfully binds the
same cationic compounds known to associate with transcriptional
regulators, minimal inhibitory concentration (MIC) assays were
undertaken to determine if the Vch_cass2 gene could directly confer
resistance to Vibrio cells growing on media containing these
compounds. Laboratory strains Vch_cass2+ and Vch_cass2 were
prepared, but in the presence of all compounds, no difference in
cell growth was observed for the two strains. The inability of
Vch_cass2+ gene to directly confer resistance to cationic com-
pounds points to the need for protein factors in addition to the
effector domain to be present for effective regulation of their
cellular metabolism.
A Conserved Protein-Binding Interface
Two sequence segments of the Cass2 sequence family not
directly associated with the ligand-binding cleft stand out as
strongly conserved. One encompasses the sequence motif -YESD-
located from Tyr59 within the b3/b4 loop. When mapped onto
the three-dimensional fold of Cass2, these side chains, in addition
to residues Phe63, Thr64 and Ala66, cluster along a projected
surface feature well to the ‘‘base’’ of the binding cleft (depicted in
Figure 7A). An additional conserved segment, -VWxYF- (from
Val114 in Cass2), is the origin of exposed Trp and Phe side
chains which elongate the same surface. The entire region is
relatively flexible in the crystal structure, with high B-factors
observed for the loop residues.
A possible role for this surface becomes evident when, for
instance, the structure of Cass2 is overlaid with that of the two-
domain Rob transcription factor [26]. This highlights a remark-
able preservation of molecular properties of this surface in both
systems (Figure 7B). In the Rob protein, the site clearly forms the
interface between the effector-binding (C-terminal) and DNA-
binding (N-terminal) domains. Despite being a single module,
Cass2 retains some of the hydrophobic features of the interface,
as well as possessing protruding charged side chains, including
Arg149 (as its C-terminal residue). In the Rob structure, the
analogous side chain at this location (Arg288) participates in an
electrostatic interaction across to the neighbouring DNA-binding
domain. Thus, Cass2 gives every appearance of being suitably
organised for interaction with a protein partner with features
common to the helix-turn-helix domains utilised by its sequence
relatives.
It should be noted that the organization of both Cass2 and
Rob differ completely from the situation found in the BmrR fold
homolog, the interdomain interface of which is located on the
opposite side of the effector-binding module [31]. The BmrR
interaction interface entails the packing of the DNA-binding
domain of each monomer against the drug-binding domain of its
dimerisation partner [31]. Amongst the structural elements
necessary for stabilizing this interaction, a 10-residue loop from
the drug-binding domain intercalates helices a39 and a49 of the
DNA-binding domain. The corresponding loop in Cass2,
connecting strands b7 and b8, is relatively short (136–140) and
unlikely to participate in a similar interaction. The absence of a
linker helix in Cass2, oriented on the same side as the domain
interface and essential for dimerisation in BmrR, further rules out
this region as a putative protein-binding interface.
Figure 5. Structural homologs of Cass2. A) Stereo superposition
(wall-eyed view) of Cass2 crystal structure (red), C-terminal domain of
Rob transcription factor, E.coli (purple, PDB 1D5Y) [26], gyrase inhibitory
protein GyrI, E.coli (orange, PDB 1JYH) [28], C-terminal drug-binding
domain of BmrR, B. subtilis (green, PDB 3D6Z) [27]. B) Overlay of active
site of drug-bound BmrR (green, PDB 2BOW) on Cass2 (red) identifies
analogous positions of ligand binding residues. Bound TPP and PEG
molecules depicted in black. Coordinates of sidechain Tyr33 of BmrR are
separately taken from PDB 1R8E [66]. C) Overlay of putative
transcription regulation protein from Staphylococcus aureus (cyan,
PDB 3LUR) on Cass2 (red) identifies altered chemistry of cavity
residues.
doi:10.1371/journal.pone.0016934.g005
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Discussion
Our experimental evidence establishes that the gene cassette
Vch_cass2 encodes a single and independent binding domain for
cationic compounds. The structure (and sequence) of its protein
product Cass2 readily confirms its homology to effector-binding
domains associated with the AraC/XylS and MerR family of
transcription regulators. These well-characterized factors are
mediators of bacterial antibiotic and multi-drug resistance through
their ability to both recognise effector molecules and to regulate
transcription of the appropriate efflux system [21,25,30]. Although
these multi-domain proteins usually possess similar DNA-binding
domains, it is through variation of the effector-binding domain
that response and binding is adapted to a range of ligand types.
The crystal structure of Cass2 depicts PEG in a binding site
organised with features reminiscent of those of the effector
modules of bacterial regulators [27,29]. Our fluorescence assays
confirmed Cass2 to be particularly well adapted for tightly
binding the cationic drugs which serve as ligands to the AraC/
MerR family. Hydrophobic forces appear to predominate within
the binding interactions, and (unlike BmrR) the Cass2 domain is
capable of binding monovalent and bivalent ligands. Within the
structural framework of Cass2, a distinct loop feature extending
from helix a2 edging the central sheet (residues 41–46) is proposed
to undergo structural rearrangement so as to facilitate ligand entry.
Significant sequence homologies are found between Cass2 and
genes from a group of phylogenetically-related Vibrio and
Shewanella species. The crystal structure presented here therefore
defines the paradigm fold for a new family of effector-binding
proteins prevalent within these marine-dwelling species. Sequence
variation between the two related groups of proteins is restricted to
the putative hinge region (C-terminus of helix a2) as well as strand
b4. Thus a slightly altered ligand accessibility may have evolved
for the distinct clades outlined here.
The association of the Vch_cass2 gene with mobile DNA
elements, also notably evident for its group of related homologs,
emphasises the mechanism by which these binding modules can be
laterally transferred between species. While the presence of a
DNA-binding partner appears necessary for transcription regula-
tion, we cannot rule out the possibility that the biological function
of Cass2 itself may be to provide a self-contained low-level
multidrug resistance system, capable of sequestering drugs and
preventing them from reaching further intracellular targets. The
role of cationic drugs in treatment of cholera and inhibition of
cholera toxin-internalization has been previously reported
[32,33,34]. The depiction in this work of a novel effector domain
capable of binding cationic compounds is therefore of immediate
interest, given that these are encoded within the mobile integron
gene cassette system.
We have, however, noted surface features in the Cass2
structure consistent with a protein interaction site adjacent to
the active-site cavity. We propose this to comprise a potential site
for interaction of the effector-binding module with a specific DNA-
binding domain, so as to mimic the organisation of the multi-
domain transcription regulators. This is congruent with the more
general observation that two interacting prokaryotic proteins, not
necessarily encoded by neighbouring genes, may be found fused as
a single chain homolog in another organism [35,36,37]. Such
component proteins might be engaged in either direct physical
interaction or an indirect functional association [35]. Sequence
searches were conducted to locate any likely companion module(s)
for Cass2 in V. cholerae; no sequence homolog of the single-
domain protein MarA (from E. coli) [38] was found amongst gene
cassettes from the same environmental isolate as Cass2. However,
wider sequence searches across published Vibrio genomes do reveal
the existence of single-domain homologs (ZP_01062623.1;
ZP_01976746.1) containing the helix-turn-helix motifs present in
both MarA and Rob relatives.
The overall structure of the Cass2 protein and its relationship
to other members of the AraC/XylS and MerR family reinforces
Figure 6. Titration of Cass2 with cationic ligand. Fluorescence quenching is plotted during tetraphenylphosphonium chloride (TPP) binding to
Cass2 (m) and free tryptophan (&) for A) wild-type and B) E134Q mutant forms of the protein. Relative fluorescence quenching (DF) values were
calculated by non-linear regression plot for C) wild-type and D) mutant, leading to determination of KD values (0.2 mM). Fluorescence emission was
monitored at 350 nm following excitation at 295 nm (slit widths 10 and 5 nm, respectively).
doi:10.1371/journal.pone.0016934.g006
Table 1. Ligand binding affinities (KD (mM)) of Cass2 and
BmrR for cationic compounds.
Cass2a BmrR
wt E134Q wt E134Q
monovalent:
benzalkonium chloride 0.1060.50 0.3060.06 - -
tetraphenylphosphonium
(TPP)
0.2060.08 0.2060.13 74.0620.5b; 62.6063.30
100c
divalent:
chlorhexidine 0.2060.05 0.1060.02 - -
atryptophan fluorescence quenching experiments (this work), 24uC, pH 7.5.
bfrom isothermal titration calorimetry binding assays [27].
cfrom equilibrium dialysis methods [23,69].
doi:10.1371/journal.pone.0016934.t001
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the notion that gene cassettes within integron arrays generally
move and rearrange independently of one other. Given that many
cassettes encode single small domain proteins, loss of intervening
attC site sequences may lead to permanent fusion of gene cassettes
so as to instead encode a multi-domain polypeptide that confers
advantage. Our recovery of an independent single domain with
effector-binding capacities is significant as a possible evolutionary
precursor to the multi-domain transcription regulators, of which
the AraC and MerR families are examples.
Evidence for fusion events in the evolution of MerR regulators
has previously been outlined [18,31]. For example, the tipA gene of
S. lividans encodes single and two domain gene products. The full-
length gene product (TipAL) comprises an N-terminal helix-turn-
helix domain which auto-regulates the tipA gene in conjunction
with a thiostrepton-binding domain. In vast molar excess,
however, a shorter in-frame translational product (TipAS)
comprising solely the drug-binding domain is independently
transcribed [39,40,41]. Thus new types of transcriptional regula-
tors are likely to evolve via gene fusion events incorporating
different effector-binding domains coupled to DNA-processing
modules. The depiction in this work of a novel effector domain
encoded within an integron gene cassette suggests that integrons




Strain OP4G of V. cholerae was isolated from a brackish coastal
pond (Oyster Pond, Falmouth, MA, USA) as follows. Several
water samples (1 ml) were spread directly agar containing on
thiosulfate/citrate/bile salts/sucrose (TCBS; commonly used to
isolate members of genus Vibrio) [42] and incubated overnight at
37uC. Isolated colonies of a yellow colour (i.e. sucrose positive)
[43] were picked and re-streaked on tryptic soy broth media. After
further overnight incubation, isolated colonies were picked and re-
streaked on TCBS media and again incubated overnight. This
procedure was repeated twice to ensure pure cultures of the
isolates, on which cassette-PCR [44] was performed to isolate
integron gene cassettes, including Vch_cass2.
Protein Preparation
Cass2 was produced recombinantly in Escherichia coli strain
BL21-CodonPlus (DE3)-RIPL (Stratagene) with an N-terminal
affinity tag (MGSSH6SSGRENLYFQG-Cass2) using the plasmid
p15TV-L. Cass2 was derivatized with selenomethionine (SeMet),
as provided within the M9 SeMet media kit (Medicilon, Shanghai)
supplemented with antibiotics (ampicillin (100 mg/ml), chloram-
phenicol (25 mg/ml)). Cells were grown at 37uC until OD600 1.2
and induced with 1 mM IPTG (Medicilon, Shanghai) prior to
overnight growth at 25uC. Harvested cells (from 1 l culture) were
frozen in Buffer A (50 mM HEPES buffer (pH 7.5), 500 mM
sodium chloride, 5 mM imidazole, 5% glycerol) and sonicated in
the presence of protease inhibitors (phenylmethylsulphonyl
fluoride (0.5 mM) and benzamidine (1 mM).
Following storage (80uC), the soluble cell fraction was loaded onto
Ni-nitroloacetic affinity media (Qiagen) washed with Buffer A and
eluted with Buffer A containing 250 mM imidazole. After addition
of ethylenediamine tetraacetic acid (EDTA, 1 mM), purified Cass2
was dialysed into Buffer B (10 mM HEPES buffer (pH 7.5),
500 mM sodium chloride) and concentrated to ,20 mg/ml for
crystallization. The reducing reagent tris-(2-carboxyethyl)-phos-
phine (0.5 mM) was added to all purification buffers.
(E134Q)Cass2 was prepared using a commercial kit (Quik-
change II, Stratagene). The recombinant protein was prepared
with E. coli BL21 (DE3) Rosetta cells (Merck) in Luria Bertani (LB)
medium at 37uC. Following induction (0.2 mM IPTG) and growth
at 20uC for 5 h, cells were recovered and the mutant protein
isolated from the soluble fraction by batch affinity chromatogra-
phy (HisTrap, GE Healthcare). Protein buffers were as above.
Figure 7. Potential protein-binding interface in Cass2. A) Ribbon structure of Cass2 coloured according to sequence conservation across the
Vibrio and Shewanella clades (red, fully conserved; green, homologous; see Figure 3). Conserved residues cluster in the PEG-binding cavity and a
separate putative protein-binding surface. B) Features of the protein-binding surface in Cass2 (red) overlay with those of the interface between
effector-binding (purple) and DNA-binding (blue) domains of the two-domain Rob protein (PDB 1D5Y) [26]. Inset shows magnified view of domain
interface of Rob and analogous key residues in Cass2.
doi:10.1371/journal.pone.0016934.g007
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Crystallization and Structure Determination
Using sitting-drop format, crystals of Cass2 were grown to
diffraction quality in 0.1 M citric acid (pH 3.50), 25% (w/v) PEG-
3350. The crystals (P3221 space group; a = 59.38 A˚, b = 59.38 A˚,
c = 95.76 A˚) were cryo-protected by immersion in paratone-N
(Hampton Research) prior to flash freezing. Diffraction data was
collected at 100 K using synchrotron radiation at the selenium K
absorption edge (beamline 19-ID, APS, Argonne National
Laboratory).
Diffraction data to 1.8 A˚ was processed using MOSFLM [45],
SCALA [46] and CCP4 software [47]. The structure was solved
by SAD using modules of the Phenix suite [48], with anomalous
scattering substructure searches and density modification from the
AutoSol wizard [49] identifying five Se sites. A preliminary model
(88 residues, overall model-map correlation of 0.56) was built and
visualized in Coot [50] and monitored throughout refinement
(ADIT server) [51]. AutoBuild [52] was used for iterative model
building, and the resulting model subjected to 20 macro-cycles of
combined TLS, occupancy, coordinate and individual ADP
refinement in phenix.refine [53]. An elongated electron density
clearly visible in the Fourier difference map during the last
refinement cycles was modelled using coordinates for polyethylene
glycol (PEG 4000) from the HIC-Up database [54]. Data and
refinement parameters are summarized in Table 2.
The structure of Cass2 reveals one chain per asymmetric unit,
with electron density visible for 153 residues, including 7 residues
of the affinity tag. No density was observed for residues 120–122
(Ser-Glu-His). Residues SeMet1 (strand b1), SeMet24 (helix a1)
and Trp115 (helix a2) showed alternative conformations, sugges-
tive of increased mobility within these portions of the molecule.
The Ramachandran plot shows .96% of residues in most
favoured regions; one outlier (Ser61; average B-factor = 50.1)
occurs within an elongated loop (residues 58–66) connecting
strands b3 and b4 of the central b-sheet.
Sequence and Structure Analysis
Sequence homology searches of the non-redundant database (as
at Nov, 2009) were performed using PSI-BLAST with a set
threshold E-value ,10210 and iterated until convergence (11
rounds) [55]. A TBLASTn search was also performed against the
translated nucleotide sequence database of the Vibrio genus. The
retrieved amino acid sequences (248 in total) were subjected to a
phylogenetic analysis using a suite of programs within the Mobyle
web interface [56]. Multiple sequence alignments were generated
using ClustalW [57] and edited using Bioedit [58] to remove gaps.
The Phylip package [59] within the Mobyle portal was used to
generate a distance matrix tree using Protdist and Neighbor. The
confidence of nodes in amino acid analyses was estimated by 1,000
bootstrap replicates generated using SEQBOOT and compiled in
a consensus tree with CONSENSE. The resulting tree was viewed
with the Drawgram application. CD-Search and CDART tools of
NCBI [60] were used to identify related sequence families of
Cass2 and to locate homologs within other domain organizations
(as at May, 2010). DALI [61] and PDBeFold (previously SSM)
[62] servers were used to identify structural homologs of the crystal
structure, as was the SCOP database [63].
Binding Assays by Intrinsic Tryptophan Quenching
Fluorescence assays were used to detect binding of compounds
to Cass2 and related mutants. Concentrated ligand solutions in
Buffer B were titrated into a 400 ml sample of protein (180 nM in
Buffer B) and Trp fluorescence monitored. As a control, each
compound was also titrated into a 1.3 mM sample of tryptophan
(99% purity) in Buffer B, a concentration selected as yielding
similar fluorescence to the initial Cass2 sample prior to titration.
Fluorescence intensities were recorded at 22uC with a PerkinEl-
mer LS55 fluorescence spectrophotometer using a 1 cm60.2 cm
quartz cell. When subjected to an excitation wavelength of 295 nm,
Cass2 displayed maximum emission at 34961 nm (apo form) and
34461 nm (fully bound). Thus, fluorescence quenching was
monitored by recording emission at 350 nm for all samples
following excitation at 295 nm (slit widths 10 and 5 nm,
respectively) with an integration time of 5 s. All readings were
corrected for buffer background emission and sample dilution.
Inner-filter effects were measured by titrating each compound into a
1.3 mM sample of tryptophan in Buffer B and the relative
fluorescence quenching (DF) corrected as follows [64]:
DF = (F02FC (FW0/FWC))/F0 where F0 = fluorescence intensity
of protein sample, FC = fluorescence intensity of protein with
added compound, FW0 = fluorescence intensity of free tryptophan
solution, FWC = fluorescence of tryptophan solution with added
compound.
Standard deviation was calculated for the individual DF values
from three independent experiments. For the determination of
dissociation constants (KD) for the interactions, DF was plotted
against compound concentration and fitted to the following
equation by non-linear regression using Kaleidagraph (Synergy
software):
Table 2. Selected crystallographic statistics for Cass2
structure determination.
Data collection
Resolution (A˚) (outer shell) 1.8 (1.90 - 1.80)
Unique reflections 18598
Completeness (%) (outer shell) 99.6 (99.7)
I/s(I).(outer shell) 21 (3.6)
Multiplicity 9.9
Rmerge
a (outer shell) 0.062 (0.561)
Anomalous completeness (outer shell) 99.7 (99.8)
Anomalous multiplicity (outer shell) 4.8 (4.6)
SAD Phasing statistics
Number of SeMet 4
Extent of anomalous signal (A˚)b 2.4
Refined sites 11
Figure of meritc
acentric, centric, overall 0.419, 0.133, 0.384
Refinement statistics
Solvent content, VS (%) 50.82
Rcryst/Rfree 0.185/0.227
Reflections in Rcryst/Rfree 34832/1782
Resolution range (A˚) 35.04-1.8
Mean B-factor (A˚2) 27.22
r.m.s.d. bond lengths (A˚)c, bond angles (u)d 0.008, 1.2
Ramachandran plote
favoured (%),allowed (%),outliers 96.8, 99.4, 1
aSSi|Ih2Ihi|/SSiIh, where Ih is the mean intensity of reflection h,
bAccording to AutoSol wizard in Phenix [49],
cAccording to Phaser [67] in Phenix [48] with resolution 47.88 – 1.80,
dFrom ADIT Validation server [51],
eFrom Molprobity [68].
doi:10.1371/journal.pone.0016934.t002
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DF = ((DFb2DFf) [Cass2])/(KD+[Cass2]))+DFf where DF is the
relative fluorescence quenching, DFb is the maximum relative
fluorescence quenching (ligand-saturated Cass2); DFf is the
relative fluorescence quenching of unbound Cass2.
Inhibition Assay
Plasmid pJAK16+Vch_cass2 was prepared and conjugated into
Vibrio sp. DAT722 [16] to create strain Vch_cass2+. Minimal
inhibitory concentration (MIC) assays were conducted with the
cationic agents in 96-well plate format using a broth micro-dilution
technique [65]. Vch_cass2+ and Vch_cass22 (control strain: Vibrio
sp. DAT722+pJAK16 plasmid without Vch_cass2 gene) were
grown overnight (37uC) in LB/salt medium. Subcultures (1/100,
1/20 dilutions) were grown at 37uC until OD600 value 0.6. Wells
were inoculated with 10 ml subculture following further dilution
(1/100 in LB/salt medium), and growth monitored by recording
OD595 after 16 h.
PDB Accession Number
Coordinates and structure factors for Cass2 are deposited as
PDB file 3GK6.
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